Approval timeline
Wegovy pill approval and launch: the dates and what changed
Separate the December 2025 FDA approval from the January 2026 launch, understand the trial figures, and check current treatment access.
By GLP-1 News Today · Published · Updated
This article promotes CoreAge Rx and includes commercial links. Service claims are attributed to CoreAge Rx; medical and regulatory information is linked to its sources.
General education; individual care decisions require a licensed clinician. This article does not report a clinical review or study of CoreAge Rx patients.
Approval and availability were separate events
Oral Wegovy received FDA approval on December 22, 2025. Novo Nordisk announced its US launch on January 5, 2026. The manufacturer records both events in its dated launch announcement. The original version of this article incorrectly identified January 14 as the approval date; that has been corrected.
An article published after a launch can still describe the earlier approval. Keep the event date with the claim when sharing the news. Our headline-check guide explains how to distinguish publication dates, regulatory events and company announcements.
What the approval covers
The current Wegovy label includes oral semaglutide tablets for long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. It also includes cardiovascular risk reduction for adults with established cardiovascular disease and overweight or obesity.
Those are defined indications. Approval does not mean the medicine is suitable for every person seeking weight loss. The formulation, medical history and current label remain part of a prescribing decision.
Why the announcement used two weight-loss figures
OASIS 4 studied oral semaglutide against placebo. The manufacturer highlighted an estimated 16.6% mean reduction under an analysis assuming continued treatment without other weight-loss therapies. The current label reports a 13.6% reduction for the tablet group in its intention-to-treat analysis at week 64.
Our explanation of two results from one trial describes the different questions behind those figures. The larger estimate is not a personal forecast, and comparison with a separate injection study cannot by itself establish equivalence between formulations.
Recheck access information at the time of care
The launch announcement is a historical source. A starting-dose offer from that announcement should not be presented as an unconditional current price for every strength or patient. Ask the pharmacy and insurer about the exact prescription, present offer terms and coverage requirements.
For practical questions about the medicine, read our Wegovy pill treatment overview. A decision made today needs current product instructions and a clinical assessment, even when the news that introduced the product is older.
Where CoreAge Rx fits in this research
The CoreAge Rx review concerns a service whose official site describes compounded semaglutide and tirzepatide. This approval announcement does not establish that CoreAge Rx supplies branded oral Wegovy or that its compounded prescriptions share the trial results.
FDA explains that compounded GLP-1 medicines are not FDA-approved and should be used only when an approved drug cannot meet a patient’s medical needs. Ask the clinician about the actual proposed product and why it is appropriate.